Results 111 to 120 of about 33,667 (245)

Cardiovascular preventive role of thiazolidinedione in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention

Journal of Diabetes Investigation, EarlyView.
Among patients with type 2 diabetes undergoing percutaneous coronary intervention, thiazolidinedione use was independently associated with a significantly reduced risk of a composite of myocardial infarction, stroke, and all‐cause death, notably without an increased risk of admission for heart failure. ABSTRACT Background Thiazolidinediones (TZD) are a
Jinkwon Kim, Jimin Jeon, Joonsang Yoo, Minyoul Baik, Seok‐Jae Heo, Ji Woong Roh   +5 more
wiley   +1 more source

Spironolactone for the treatment of hypercalciuric hypocalcemia

, 2002
A patient with hypocalcemia and hypomagnesemia, and renal wasting of both cations, is presented. This patient had a dramatic calcium response to treatment with spironolactone. The possible diagnoses and mechanisms of response are discussed.
Al-Shoumer, KAS, Al-Gharabally, A, Doi, SAR   +2 more
core   +1 more source

Spironolactone in cardiovascular disease: an expanding universe? [version 1; referees: 2 approved]

F1000Research, 2017
Spironolactone has been marketed for over half a century as a ‘potassium-sparing diuretic’, used primarily in patients with ascites. With the realization that primary aldosteronism is the most common (5-13%) form of secondary hypertension, it has become ...
John W. Funder
doaj   +1 more source

Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk

Journal of Internal Medicine, EarlyView.
Abstract Polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome, affects 10%–13% of women of reproductive age and remains underdiagnosed despite its substantial health burden. The introduction of the new PMOS nomenclature in 2026 reflects a fundamental shift in understanding the condition as a lifelong endocrine ...
Maria Forslund, Johanna Melin, Anju E. Joham, Terhi T. Piltonen, D. Aled Rees, Helena J. Teede   +5 more
wiley   +1 more source

Spironolactone treatment for aortic valve regurgitation

, 2012
BACKGROUND AND AIM OF THE STUDY : Aortic regurgitation (AR) is a disease for which there is currently no effective medical treatment. It has been shown previously in an experimental model of AR that the renin-angiotensin-aldosterone system (RAAS) plays ...
Roussel, Élise, Arsenault, Marie, Lachance, Dominic., Zendaoui, Adnane, Couët, Jacques   +4 more
core  

Advanced Conduction Disease After Incident Heart Failure in Myotonic Dystrophy Type 1

Pacing and Clinical Electrophysiology, EarlyView.
Central Figure. Advanced Conduction Disease After Incident HF in Myotonic Dystrophy Type 1. ABSTRACT Background Myotonic dystrophy type 1 (DM1) is associated with progressive cardiac conduction disease, heart failure (HF) and increased mortality. However, the association of incident HF with conduction disease and survival in DM1 is not well defined ...
Isadora Guarino, Lauren Elman, Gregory Supple, Saman Nazarian   +3 more
wiley   +1 more source

Spironolactone increases permeability of visceral sheep peritoneum

, 2009
Aldosterone is a key component of the renin-angiotensin-aldosterone system, and spironolactone, an aldosterone receptor blocker, shows beneficial effects in patients with end-stage renal disease and heart failure.
Karioti, A., Deligiorgi, T., Arampatzis, S., Hatzoglou, C., Stefanidis, I., Zarogiannis, S., Kourti, P., Liakopoulos, V., Molyvdas, P. A., Giannopoulou, M., Gourgoulianis, K.   +10 more
core  

Development of quantitative determination method for spironolactone in compounded syrups.

, 2017
Spironolactone is a potassium-sparing diuretic used in congestive heart failure, oedema, hepatic cirrhosis, nephrotic syndrome, hypokalaemia and management of hypertension.
Alfred-Ugbenbo, D., Zdoryk, O. A.
core   +1 more source

Efficacy of spironolactone in treating hidradenitis suppurativa in women of childbearing age: a single-center retrospective analysis

International Journal of Women's Dermatology
Background:. Hidradenitis suppurativa (HS) is a chronic skin disease characterized by recurrent nodules that affect areas with a high density of apocrine sweat glands, such as the axillae and groin.
Suma V. Gangidi, BS, Rachel K. Greene, MD, Eric Olsen, MD, Shanelle Jackson, BS, Mio Nakamura, MD   +4 more
doaj   +1 more source

Treatment Patterns in Pediatric Hidradenitis Suppurativa: Time to Treatment Initiation, Initial Treatment, and Time to Switching

Pediatric Dermatology, EarlyView.
ABSTRACT Background Hidradenitis suppurativa (HS) causes significant morbidity in children. Treatment patterns across sex, race, and ethnicity in pediatric HS have not been thoroughly evaluated. We aim to characterize treatment patterns in pediatric HS, including (1) time to treatment initiation, (2) first prescribed HS treatment, and (3) time to ...
Shaliz Aflatooni, Andrea Ure, Kimberly Smart, Julian A. Cortes, Gabriela Palma, Nicole Johnsen, Yvonne Nong, April W. Armstrong   +7 more
wiley   +1 more source